• About
• Links
• Contact
• Sitemap

Molecular Diagnostics: Major World Markets

Molecular diagnostics (also known as nucleic acid testing) has emerged as a field that promises to renew technological progress in the clinical laboratory and to vastly improve patient care. Although it has been a slower than anticipated adoption in the clinical laboratory setting, molecular diagnostics has begun to overcome the impediments of incomplete genetic knowledge, the development of new technology platforms, and the communication of their use and efficacy to lab personnel and clinicians alike.

A series of technologies developed over the years to address the challenges of molecular diagnostics include eight major areas: amplification technologies (gene and signal), blotting technologies, electrophoretic technologies, microarray technologies, probe technologies, restriction fragment-length polymorphism (RFLP) analysis, RNA inhibition analysis, and single nucleotide polymorphism (SNP) analysis and software. Further, there is significant overlap among these technologies in that they can support one another. These developments have set the stage for excellent growth potential in this marketplace.

Kalorama’s Molecular Diagnostics: Major World Markets completely re-examines the molecular diagnostics market and expands its well respected previous editions. The report features:

• Market Potential in terms of number of tests (testing volume) and market size (dollar volume) through 2016 for strategic planning and new product consideration.
• 110 Tables and Figures detailing the data and trends in each country and segment/subsegment for quick reference and encorporation into proposals, internal memos and business plans.
• In-depth Profiles (averaging 5 pages each) of top 10 competitors, detailing product offerings, recent announcements and acquisitions, and strategies..
• Discussion of the Major Technologies, including developments, products, benefits and drawbacks of:
  • amplification technologies (gene and signal)
  • blotting technologies
  • electrophoresis technologies
  • microarray technologies
  • probe technologies
  • restriction fragment-length polymorphism (RFLP)
  • RNA inhibition analysis
  • single nucleotide polymorphism (SNP) analysis
• 14 High Level Conclusions about the marketplace, each with a discussion of its strategic implication to assist executives in understanding how the trends and data affect their business decisions.
• Two tables (over 70 pages in length) list both marketed products and key “home-brew” molecular tests currently in use.

(The U.S. Market for Molecular Diagnostics) to include all seven of the major world healthcare markets, including:

• France
• Germany
• Italy
• Japan
• Spain
• The United Kingdom
• The United States

This definitive and comprehensive assessment of the molecular diagnostics market provides market potential in both testing volume and dollar volume for each major country in the following test segments and subsegments:

• Blood Banking and Plasmapheresis
  • Human Immunodeficiency Virus (HIV)
  • Hepatitis C Virus (HCV)
  • Hepatitis B Virus (HBV)
  • Hepatitis A Virus (HAV)
  • Human T-Cell Lymphotropic Virus (HTLV)
  • West Nile Virus (WNV)
  • Other
• Genetic Analysis
  • Heterozygote Testing
  • Presymptomatic Testing
  • Prenatal Testing
  • Newborn Screening
• Oncology
  • Cancer Management
  • Cancer Susceptibility
• Pharmacogenetics
  • HIV/AIDS
  • Neuropharmacology
  • Immune Disease
  • Cancer
  • Other
• Infectious Disease
  • Chlamydia trachomatis (CT)
  • Neisseria gonorrhoeae (NG)
  • Pneumonia
  • Human Immunodeficiency Virus (HIV)
  • Hepatitis B Virus (HBV)
  • Hepatitis C Virus (HCV)
  • Humanpapilloma Virus (HPV)
  • Mycobacterium tuberculosis (MT) (Tuberculosis [TB])
  • Herpes Simplex Virus (HSV)
  • West Nile Virus (WNV)

The report also details the technologies and products competing and shaping the markets, describes the market characteristics of the various segments, provides 14 vital conclusions along with their strategic implications for marketers, and profiles in depth the top market participants.

The analysis presented in this report is based on data from a combination of company, government, industry, and institutional and private sources. It includes information from extensive literature reviews, as well as interviews and discussions with experts in the field, including molecular biologists, laboratory medicine professionals, pathologists, research scientists, business development managers and marketing managers.

Table of Contents

Chapter One: Executive Summary

• Background
• Scope and Methodology
• Size and Growth of Market
• Competitive Picture
• Market Trends and Factors

Chapter Two: Introduction

• Background
• Market Erosion
• Clinical Relevance
• Cost-Benefit Relationships
• Scientific Limitations
• Essential Scientific Foundations
• Genomics
• Genes, Functional Genomics and Disease
• Proteomics

Chapter Three: Molecular Diagnostics Technologies

• Background
• Amplification Technologies
• Gene Amplification
• Signal Amplification
• Probe Technologies
• Microchip Technologies
• Electrophoretic Technologies
• Blotting Technologies
• Single Nucleotide Polymorphism (SNP) Analysis
• Restriction Fragment Length Polymorphism (RFLP) Analysis
• RNA Inhibition (RNAi) Analysis
• Biophotonics

Chapter Four: Applications of Molecular Diagnostics

• The Testing Environment
• Regulatory Issues and Home-Brew Assays
• Molecular Diagnostics Test Distribution and Factors
• Privacy Issues and Legislation
• The Blood Banking Industry
• Commercial Clinical Laboratory Operations
• University/Hospital Laboratory Operations
• Projections
  • Blood Banking Analysis
  • Genetic Diseases
  • Oncology
  • Pharmacogenetics
  • Infectious Disease Testing
  • Chlamydia trachomatis
  • Neisseria gonorrhoeae
  • Pneumonia
  • Human Immunodeficiency Virus (HIV)
  • Tuberculosis
  • Hepatitis B (HBV)
  • Hepatitis C (HCV)
  • Human Papillomavirus (HPV)
  • Herpes Simplex (HSV)
  • West Nile Virus (WNV)

Chapter Five: The Market for Molecular Diagnostics

• Market Size and Trending
• Blood Bank Testing
• Gene and Chromosome Testing
• Oncology Testing
• Pharmacogenetic Testing
• Infectious Disease Testing
• Competitive Picture and Industry Structure
• Future Prospects

Chapter Six: Company Profiles

• Overview
• Abbott Diagnostics (Vysis Division)
• Bayer Diagnostics Division of Bayer Healthcare
• Biotest Diagnostics (Division of Biotest AG)
• Celera Diagnostics (Celera Genomics Group/Applera Corporation)
• Cepheid, Inc.
• Digene Corporation
• Gen-Probe Incorporated
• Innogenetics NV
• Roche Diagnostics Division/Roche Molecular Systems (F. Hoffmann-LaRoche Ltd.)
• Third Wave Technologies

Chapter Seven: Conclusions and Strategic Implications

• First Conclusion
• Implications:
• Second Conclusion
• Implications:
• Third Conclusion
• Implications:
• Fourth Conclusion
• Implications:
• Fifth Conclusion
• Implications:
• Sixth Conclusion
• Implications:
• Seventh Conclusion
• Implications:
• Eighth Conclusion
• Implications:
• Ninth Conclusion
• Implications:
• Tenth Conclusion
• Implications:
• Eleventh Conclusion
• Implications:
• Twelfth Conclusion
• Implications:
• Thirteenth Conclusion
• Implications:
• Fourteenth Conclusion
• Implications:

Appendix: Company Directory List of Exhibits Chapter One: Executive Summary

• Table 1-1: Molecular Diagnostics Technologies Description, Advantages,Disadvantages
• Table 1-2: Projected Molecular Diagnostics Market Potential in the Seven MajorWorld Healthcare Markets by Country 2006 - 2016
• Figure 1-1: Trending in the Projected Molecular Diagnostics Market Potential in the Seven Major World Healthcare Markets by Applications Segment(Blood Banking, Cancer, Infectious Disease, Gene/ChromosomeTesting, Pharmacogenetics) 2006 - 2016
• Figure 1-2: Trending in the Composition of the Projected Molecular DiagnosticsMarket Potential in the Seven Major World Healthcare Markets by Applications Segment (Blood Banking, Cancer, Infectious Disease, Gene/Chromosome Testing, Pharmacogenetics) 2006 - 2016
• Table 1-3: Key Active Competitors in the Molecular Diagnostics ProductsMarket by Technologies 2007

Chapter Three: Molecular Diagnostics Technologies

• Table 3-1: Molecular Diagnostics Technologies Description, Advantages,Disadvantages
• Table 3-2: Gene Amplification Technologies
• Table 3-3: Commonly Used Signal Amplification Technologies forGenetic Analysis

Chapter Four: Applications of Molecular Diagnostics

• Table 4-1: Commercially Available Molecular Diagnostics Tests (Company,Analyte, Test Category, Test Name, Technology)
• Table 4-2: Key “Home-Brew” Molecular Diagnostics Assays (Disease/Condition, Specimen Type, Assay Method, Turn-Around Time,Comments)
• Figure 4-1: Distribution of Molecular Diagnostics Testing by Application(Blood Bank, Cancer, Pharmacogenetic, Tissue Typing,Gene/Chromosome, Infectious Disease) 2006
• Table 4-3: Populations of the Seven Major World Healthcare Markets2006 - 2016
• Table 4-4: Distribution of Populations of the Seven Major World HealthcareMarkets: 2006 - 2016
• Table 4-5: Potential Test Volumes for Molecular Diagnostics in the Seven MajorWorld Healthcare Markets by Testing Area (Blood Banking, Gene/Chromosome Disease, Oncology, Pharmacogenetics,Infectious Disease) 2006 - 2016
• Table 4-6: Distribution of Potential Test Volumes for Molecular Diagnostics in theSeven Major World Healthcare Markets by Testing Area (BloodBanking, Gene/Chromosome Disease, Oncology, Pharmacogenetics, Infectious Disease) 2006 - 2016
• Table 4-7: Estimated Blood/Plasma Donation Levels in the Seven Major World Healthcare Markets 2006 - 2016
• Table 4-8: Potential Levels of Molecular Testing in Blood Banking in theSeven Major World Healthcare Markets 2006 - 2016
• Table 4-9: Commercially Available Molecular (Nucleic Acid) Tests for Blood,Plasma and Organ Donor Screening in the United States (TradeName, Format, Sample, Use, Manufacturer, Approval Date) 2006
• Table 4-10: Potential Levels of Molecular Testing in Blood Banking inFrance by Category (HIV, HCV, HBV, HAV, HTLV, WNV,Others) 2006 - 2016
• Table 4-11: Potential Levels of Molecular Testing in Blood Banking inGermany by Category (HIV, HCV, HBV, HAV, HTLV, WNV,Others) 2006 - 2016
• Table 4-12: Potential Levels of Molecular Testing in Blood Banking in Italy byCategory (HIV, HCV, HBV, HAV, HTLV, WNV, Others)2006 - 2016
• Table 4-13: Potential Levels of Molecular Testing in Blood Banking inJapan by Category (HIV, HCV, HBV, HAV, HTLV, WNV,Others) 2006 - 2016
• Table 4-14: Potential Levels of Molecular Testing in Blood Banking inSpain by Category (HIV, HCV, HBV, HAV, HTLV, WNV,Others) 2006 - 2016
• Table 4-15: Potential Levels of Molecular Testing in Blood Banking in theUnited Kingdom by Category (HIV, HCV, HBV, HAV, HTLV,WNV, Others) 2006 - 2016
• Table 4-14: Potential Levels of Molecular Testing in Blood Banking in theUnited States by Category (HIV, HCV, HBV, HAV, HTLV,WNV, Others) 2006 - 2016
• Table 4-17: Key Hereditary Diseases (Condition, Incidence, andInheritance/Cause)
• Table 4-18: Potential Levels of Molecular Testing in Genetic Analysis in theSeven Major World Healthcare Markets by Category (Heterozygote, Presymptomatic, Prenatal, Newborn Screening) 2006 - 2016
• Table 4-19: Potential Levels of Molecular Testing in Genetic Analysis in theSeven Major World Healthcare Markets by Country2006 - 2016
• Table 4-20: Potential Levels of Molecular Testing in Oncology in the SevenMajor World Healthcare Markets by Category (Management vs Susceptibility) 2006 - 2016
• Table 4-21: Potential Levels of Molecular Testing in Oncology in the SevenMajor World Healthcare Markets by Country 2006 - 2016
• Table 4-22: Drugs Affected by the Cytochrome p450 System
• Table 4-23: Potential Levels of Molecular Testing in Pharmacogenetics in theSeven Major World Healthcare Markets by Category(HIV/AIDS, Neuropharmacology, Immune Disease, Cancer,Other) 2006 - 2016
• Table 4-24: Potential Levels of Molecular Testing in Pharmacogenetics in theSeven Major World Healthcare Markets by Country 2006 - 2016
• Table 4-25: Potential Levels of Molecular Testing in Infectious Disease in theSeven Major World Healthcare Markets by Category (CT, NG,Pneumonia, HIV, HBV, HCV, HPV, MT, HSV) 2006 - 2016
• Table 4-26: Potential Levels of Molecular Testing in Infectious Disease in theSeven Major World Healthcare Markets by Country 2006 - 2016

Chapter Five: The Market for Molecular Diagnostics

• Table 5-1: Projected Molecular Diagnostics Market Potential in the SevenMajor World Healthcare Markets by Country 2006 - 2016
• Table 5-2: Potential Market for Molecular Diagnostics Testing in France byTesting Area (Blood Banking, Gene/Chromosome Disease,Oncology, Pharmacogenetics, Infectious Disease) 2006 - 2016
• Table 5-3: Potential Market for Molecular Diagnostics Testing in Germany byTesting Area (Blood Banking, Gene/Chromosome Disease,Oncology, Pharmacogenetics, Infectious Disease) 2006 - 2016
• Table 5-4: Potential Market for Molecular Diagnostics Testing in Italy byTesting Area (Blood Banking, Gene/Chromosome Disease,Oncology, Pharmacogenetics, Infectious Disease) 2006 - 2016
• Table 5-5: Potential Market for Molecular Diagnostics Testing in Japan byTesting Area (Blood Banking, Gene/Chromosome Disease,Oncology, Pharmacogenetics, Infectious Disease) 2006 - 2016
• Table 5-6: Potential Market for Molecular Diagnostics Testing in Spain byTesting Area (Blood Banking, Gene/Chromosome Disease,Oncology, Pharmacogenetics, Infectious Disease) 2006 - 2016
• Table 5-7: Potential Market for Molecular Diagnostics Testing in the UnitedKingdom by Testing Area (Blood Banking, Gene/ChromosomeDisease, Oncology, Pharmacogenetics, Infectious Disease)2006 - 2016
• Table 5-8: Potential Market for Molecular Diagnostics Testing in the UnitedStates by Testing Area (Blood Banking, Gene/ChromosomeDisease, Oncology, Pharmacogenetics, Infectious Disease)2006 - 2016
• Figure 5-1: Trending in the Potential Markets for Molecular Diagnostics in theSeven Major World Healthcare Markets 2006 - 2016
• Figure 5-2: Trending in the Composition of Potential Markets for MolecularDiagnostics in the Seven Major World Healthcare Markets2006 - 2016
• Table 5-9: Table 5-8Potential Market for Molecular Diagnostics Testing in the Seven Major World Healthcare Markets by Testing Area (Blood Banking, Gene/Chromosome Disease, Oncology, Pharmacogenetics, InfectiousDisease) 2006 - 2016
• Figure 5-3: Trending in the Potential Test Volume for Molecular Diagnosticsin the Seven Major World Healthcare Markets by Testing Area(Blood Banking, Gene/Chromosome Disease, Oncology,Pharmacogenetics, Infectious Disease) 2006 - 2016
• Figure 5-4: Trending in the Composition of Potential Test Volume for Molecular Diagnostics in the Seven Major World Healthcare Markets byTesting Area (Blood Banking, Gene/Chromosome Disease,Oncology, Pharmacogenetics, Infectious Disease) 2006 - 2016
• Table 5-10: Projected Blood Banking and Plasmapheresis Molecular DiagnosticsTesting Market Potential in the Seven Major World HealthcareMarkets by Country 2006 - 2016
• Figure 5-5: Trending in the Projected Blood Banking and PlasmapheresisMolecular Diagnostics Testing Market Potential in the SevenMajor World Healthcare Markets 2006 - 2016
• Figure 5-6: Trending in the Projected Blood Banking and PlasmapheresisMolecular Diagnostics Potential Testing Volume in the SevenMajor World Healthcare Markets 2006 - 2016
• Table 5-11: Projected Blood Banking and Plasmapheresis MolecularDiagnostics Testing Volume Potential in the Seven Major WorldHealthcare Markets by Test Type (HIV, HCV, HBV, HAV,HTLV, WNV, Others) 2006 - 2016
• Figure 5-7: Trending in the Composition of the Projected Blood Banking and Plasmapheresis Molecular Diagnostics Testing Volume Potentialin the Seven Major World Healthcare Markets 2006 - 2016
• Table 5-12: Projected Blood Banking and Plasmapheresis Molecular DiagnosticsTesting Volume Potential in France by Test Type (HIV, HCV,HBV, HAV, HTLV, WNV, Others) 2006 - 2016
• Table 5-13: Projected Blood Banking and Plasmapheresis Molecular DiagnosticsTesting Volume Potential in Germany by Test Type (HIV, HCV,HBV, HAV, HTLV, WNV, Others) 2006 - 2016
• Table 5-14: Projected Blood Banking and Plasmapheresis Molecular DiagnosticsTesting Volume Potential in Italy by Test Type (HIV, HCV, HBV,HAV, HTLV, WNV, Others) 2006 - 2016
• Table 5-15: Projected Blood Banking and Plasmapheresis Molecular DiagnosticsTesting Volume Potential in Japan by Test Type (HIV, HCV, HBV,HAV, HTLV, WNV, Others) 2006 - 2016
• Table 5-16: Projected Blood Banking and Plasmapheresis Molecular DiagnosticsTesting Volume Potential in Spain by Test Type (HIV, HCV, HBV,HAV, HTLV, WNV, Others) 2006 - 2016
• Table 5-17: Projected Blood Banking and Plasmapheresis Molecular DiagnosticsTesting Volume Potential in the United Kingdom by Test Type(HIV, HCV, HBV, HAV, HTLV, WNV, Others) 2006 - 2016
• Table 5-18: Projected Blood Banking and Plasmapheresis Molecular DiagnosticsTesting Volume Potential in the United States by Test Type(HIV, HCV, HBV, HAV, HTLV, WNV, Others) 2006 - 2016
• Table 5-19: Projected Genetic and Chromosome Molecular Diagnostics TestingMarket Potential in the Seven Major World HealthcareMarkets by Country 2006- 2016
• Figure 5-8: Trending in the Projected Genetic and Chromosome MolecularDiagnostics Testing Market Potential in the Seven Major WorldHealthcare Markets 2006 - 2016
• Figure 5-9: Trending in the Projected Genetic and Chromosome MolecularDiagnostics Testing Market Assay Volume Potential in theSeven Major World Healthcare Markets 2006 - 2016
• Table 5-20: Projected Genetic and Chromosome Molecular Diagnostics TestingVolume Potential in the Seven Major World Healthcare Markets by Application (Heterozygote Testing, Presymptomatic Disease Testing, Prenatal Testing, Newborn Testing) 2006 - 2016
• Figure 5-10: Trending in the Composition of the Projected Genetic andChromosome Molecular Diagnostics Testing Volume Potentialin the Seven Major World Healthcare Markets 2006 - 2016
• Table 5-21: Projected Genetic and Chromosome Molecular Diagnostics TestingVolume Potential in France by Application (Heterozygote Testing, Presymptomatic Disease Testing, Prenatal Testing, NewbornTesting) 2006 - 2016
• Table 5-22: Projected Genetic and Chromosome Molecular Diagnostics TestingVolume Potential in Germany by Application (Heterozygote Testing, Presymptomatic Disease Testing, Prenatal Testing, NewbornTesting) 2006 - 2016
• Table 5-23: Projected Genetic and Chromosome Molecular Diagnostics TestingVolume Potential in Italy by Application (Heterozygote Testing, Presymptomatic Disease Testing, Prenatal Testing, NewbornTesting) 2006 - 2016
• Table 5-24: Projected Genetic and Chromosome Molecular Diagnostics TestingVolume Potential in Japan by Application (Heterozygote Testing, Presymptomatic Disease Testing, Prenatal Testing, NewbornTesting) 2006 - 2016
• Table 5-25: Projected Genetic and Chromosome Molecular Diagnostics TestingVolume Potential in Spain by Application (Heterozygote Testing, Presymptomatic Disease Testing, Prenatal Testing, NewbornTesting) 2006 - 2016
• Table 5-26: Projected Genetic and Chromosome Molecular Diagnostics TestingVolume Potential in the United Kingdom by Application(Heterozygote Testing, Presymptomatic Disease Testing,Prenatal Testing, Newborn Testing) 2006 - 2016
• Table 5-27: Projected Genetic and Chromosome Molecular Diagnostics TestingVolume Potential in the United States by Application(Heterozygote Testing, Presymptomatic Disease Testing, PrenatalTesting, Newborn Testing) 2006 - 2016
• Table 5-28: Projected Oncology Molecular Diagnostics Testing Market Potentialin the Seven Major World Healthcare Markets by Country2006- 2016
• Figure 5-11: Trending in the Projected Oncology Molecular Diagnostics TestingMarket Potential in the Seven Major World Healthcare Markets2006 - 2016
• Figure 5-12: Trending in the Projected Oncology Molecular Diagnostics TestingMarket Assay Volume Potential in the Seven Major World Healthcare Markets 2006 - 2016
• Table 5-29: Projected Molecular Oncology Diagnostics Testing Volume Potentialin the Seven Major World Healthcare Markets by Application(Cancer Management vs Cancer Susceptibility) 2006 - 2016
• Figure 5-13: Trending in the Composition of the Projected Oncology Molecular Diagnostics Testing Market Assay Volume Potential in the SevenMajor World Healthcare Markets: 2006 - 2016
• Table 5-30: Projected Molecular Oncology Diagnostics Testing Volume Potentialin France by Application (Cancer Management vs CancerSusceptibility) 2006 - 2016
• Table 5-31: Projected Molecular Oncology Diagnostics Testing Volume Potentialin Germany by Application (Cancer Management vs CancerSusceptibility) 2006 - 2016
• Table 5-32: Projected Molecular Oncology Diagnostics Testing Volume Potentialin Italy by Application (Cancer Management vs CancerSusceptibility) 2006 - 2016
• Table 5-33: Projected Molecular Oncology Diagnostics Testing Volume Potentialin Japan by Application (Cancer Management vs CancerSusceptibility) 2006 - 2016
• Table 5-34: Projected Molecular Oncology Diagnostics Testing Volume Potentialin Spain by Application (Cancer Management vs CancerSusceptibility) 2006 - 2016
• Table 5-35: Projected Molecular Oncology Diagnostics Testing Volume Potentialin the United Kingdom by Application (Cancer Management vsCancer Susceptibility) 2006 - 2016
• Table 5-36: Projected Molecular Oncology Diagnostics Testing Volume Potentialin the United States by Application (Cancer Management vsCancer Susceptibility) 2006 - 2016
• Table 5-37: Projected Pharmacogenetic Molecular Diagnostics Testing MarketPotential in the Seven Major World Healthcare Markets byCountry 2006 - 2016
• Figure 5-14: Trending in the Projected Pharmacogenetic Molecular DiagnosticsTesting Market Potential in the Seven Major World HealthcareMarkets 2006 - 2016
• Table 5-38: Projected Molecular Pharmacogenetics Testing Volume Potential inthe Seven Major World Healthcare Markets by Application(HIV/AIDS Testing, Neuropharmaceutical Testing, ImmuneTherapeutics Testing, Cancer Testing, Other) 2006 - 2016
• Figure 5-15: Trending in the Projected Pharmacogenetics Molecular DiagnosticsTesting Market Assay Volume Potential in the Seven Major World Healthcare Markets: 2006 - 2016
• Figure 5-16: Trending in the Composition of the Projected PharmacogeneticsMolecular Diagnostics Testing Market Assay Volume Potentialin the Seven Major World Healthcare Markets: 2006 - 2016
• Table 5-39: Potential Pharmacogenetic Molecular Diagnostics Testing Volume inFrance by Application (HIV/AIDS Testing, NeuropharmaceuticalTesting, Immune Therapeutics Testing, Cancer Testing,Other) 2006 - 2016
• Table 5-40: Potential Pharmacogenetic Molecular Diagnostics Testing Volume in Germany by Application (HIV/AIDS Testing, NeuropharmaceuticalTesting, Immune Therapeutics Testing, Cancer Testing,Other) 2006 - 2016
• Table 5-41: Potential Pharmacogenetic Molecular Diagnostics Testing Volume inItaly by Application (HIV/AIDS Testing, NeuropharmaceuticalTesting, Immune Therapeutics Testing, Cancer Testing,Other) 2006 - 2016
• Table 5-42: Potential Pharmacogenetic Molecular Diagnostics Testing Volume inJapan by Application (HIV/AIDS Testing, NeuropharmaceuticalTesting, Immune Therapeutics Testing, Cancer Testing,Other) 2006 - 2016
• Table 5-43: Potential Pharmacogenetic Molecular Diagnostics Testing Volume inSpain by Application (HIV/AIDS Testing, NeuropharmaceuticalTesting, Immune Therapeutics Testing, Cancer Testing,Other) 2006 - 2016
• Table 5-44: Potential Pharmacogenetic Molecular Diagnostics Testing Volume inthe United Kingdom by Application (HIV/AIDS Testing, Neuropharmaceutical Testing, Immune Therapeutics Testing,Cancer Testing, Other) 2006 - 2016
• Table 5-45: Potential Pharmacogenetic Molecular Diagnostics Testing Volume inthe United States by Application (HIV/AIDS Testing,Neuropharmaceutical Testing, Immune Therapeutics Testing,Cancer Testing, Other) 2006 - 2016
• Table 5-46: Projected Molecular Diagnostics Infectious Disease TestingMarket Potential in the Seven Major World Healthcare Marketsby Country 2006 - 2016
• Figure 5-17: Trending in the Projected Infectious Disease Molecular DiagnosticsTesting Market Potential in the Seven Major World HealthcareMarkets: 2006 - 2016
• Figure 5-18: Trending in the Projected Infectious Disease Molecular DiagnosticsTesting Market Assay Volume Potential in the Seven Major World Healthcare Markets: 2006 - 2016
• Figure 5-19: Trending in the Composition of the Projected Infectious DiseaseMolecular Diagnostics Testing Market Assay Volume Potentialin the Seven Major World Healthcare Markets: 2006 - 2016
• Figure 5-20: Trending in the Projected Test Volume for Molecular Diagnosticsin Infectious Disease Testing in the Seven Major World HealthcareMarkets by Application: 2006 - 2016
• Table 5-47: Projected Molecular Diagnostics Infectious Disease Testing VolumePotential in the Seven Major World Healthcare Markets byApplication (CT, NG, Pneumonia, HIV, HBV, HCV, HPV, MT,HSV) 2006 - 2016
• Table 5-48: Projected Infectious Disease Molecular Diagnostics Potential TestingVolume in France by Application (CT, NG, Pneumonia, HIV, HBV,HCV, HPV, MT, HSV) 2006 - 2016
• Table 5-49: Projected Infectious Disease Molecular Diagnostics Potential TestingVolume in Germany by Application (CT, NG, Pneumonia, HIV,HBV, HCV, HPV, MT, HSV) 2006 - 2016
• Table 5-50: Projected Infectious Disease Molecular Diagnostics Potential TestingVolume in Italy by Application (CT, NG, Pneumonia, HIV, HBV,HCV, HPV, MT, HSV) 2006 - 2016
• Table 5-51: Projected Infectious Disease Molecular Diagnostics Potential TestingVolume in Japan by Application (CT, NG, Pneumonia, HIV, HBV,HCV, HPV, MT, HSV) 2006 - 2016
• Table 5-52: Projected Infectious Disease Molecular Diagnostics Potential TestingVolume in Spain by Application (CT, NG, Pneumonia, HIV, HBV,HCV, HPV, MT, HSV) 2006 - 2016
• Table 5-53: Projected Infectious Disease Molecular Diagnostics Potential TestingVolume in the United Kingdom by Application (CT, NG,Pneumonia, HIV, HBV, HCV, HPV, MT, HSV) 2006 - 2016
• Table 5-54: Projected Infectious Disease Molecular Diagnostics Potential TestingVolume in the United States by Application (CT, NG, Pneumonia,HIV, HBV, HCV, HPV, MT, HSV) 2006 - 2016
• Table 5-55: Key Active Competitors in the Molecular Diagnostics ProductsMarket by Technologies 2007

 

Other users found this report page using the following search terms: molecular diagnostics amplification technologies blotting technologies electrophoretic technologies microarray technologies probe technologies RFLP RNAi RNA inhibition nucleotide polymorphism SNP diagnostics homebrew markets molecular marketing regulatory issues microchip companies tissue

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.